Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.06.124 on December 21 2004

Journal of Clinical Oncology, Vol 23, No 5 (February 10), 2005: pp. 965-972
© 2005 American Society of Clinical Oncology.
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Strumberg, D.
Right arrow Articles by Seeber, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Strumberg, D.
Right arrow Articles by Seeber, S.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors

Dirk Strumberg, Heike Richly, Ralf A. Hilger, Norbert Schleucher, Sonke Korfee, Mitra Tewes, Markus Faghih, Erich Brendel, Dimitris Voliotis, Claus G. Haase, Brian Schwartz, Ahmad Awada, Rudolf Voigtmann, Max E. Scheulen, Siegfried Seeber

From the Department of Internal Medicine and Medical Oncology, West German Cancer Center, University Medical School of Essen, Essen; Department of Hematology and Medical Oncology, University of Bochum, Herne; Bayer Healthcare, Pharma Research Center, Wuppertal, Germany; Bayer Pharmaceuticals Corporation, West Haven, CT; and Jules Bordet Institute, Brussels, Belgium

Address reprint requests to Dirk Strumberg, MD, Department of Hematology and Medical Oncology, Marienhospital Herne, University of Bochum, Hölkeskampring 40, 44 621 Herne, Germany; e-mail: dirk.strumberg{at}uni-essen.de.

PURPOSE: BAY 43-9006 is a novel dual-action Raf kinase and vascular endothelial growth factor receptor inhibitor that inhibits tumor cell proliferation and angiogenesis. This study established the safety and pharmacokinetics of BAY 43-9006 in 69 patients with advanced refractory solid tumors.

PATIENTS AND METHODS: BAY 43-9006 (50 to 800 mg) was administered once or twice daily on a varying weekly schedule. Pharmacokinetic sampling was performed in all patients; preliminary tumor response was also assessed. The effect of BAY 43-9006 on phorbol myristate acetate–stimulated ERK phosphorylation in peripheral blood lymphocytes was studied using flow cytometry.

RESULTS: Mild to moderate diarrhea was the most common (55%) treatment-related adverse event. The maximum-tolerated dose was 400 mg bid continuous. Dose-limiting toxicities were grade 3 diarrhea and fatigue at 800 mg bid, and grade 3 skin toxicity at 600 mg bid. BAY 43-9006 pharmacokinetics were highly variable for single and multiple dosing, and toxicity did not appear to be dose dependent. Significant decreases of phorbol myristate acetate–stimulated ERK phosphorylation (P < .01) were identified at doses ≥ 200 mg bid continuous. Forty-five patients were assessable for efficacy; one patient had a partial response (hepatocellular carcinoma at 400 mg bid continuous), 25 patients had stable disease, with eight lasting > 6 months and five for >12 months. Eighteen patients had progressive disease, and tumor response could not be evaluated in one patient.

CONCLUSION: Oral BAY 43-9006 was well tolerated and appeared to provide some clinical benefits. Based on the results of this study, BAY 43-9006 at 400 mg bid continuous is recommended for ongoing and future studies.

Supported by Bayer Pharmaceuticals Corporation.

Terms in blue are defined in the glossary, found at the end of this issue and online at www.jco.org.

Authors' disclosures of potential conflicts of interest are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 JCOHome page
R. G. Maki, D. R. D'Adamo, M. L. Keohan, M. Saulle, S. M. Schuetze, S. D. Undevia, M. B. Livingston, M. M. Cooney, M. L. Hensley, M. M. Mita, et al.
Phase II Study of Sorafenib in Patients With Metastatic or Recurrent Sarcomas
J. Clin. Oncol., July 1, 2009; 27(19): 3133 - 3140.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
H. I. Hurwitz, A. Dowlati, S. Saini, S. Savage, A. B. Suttle, D. M. Gibson, J. P. Hodge, E. M. Merkle, and L. Pandite
Phase I Trial of Pazopanib in Patients with Advanced Cancer
Clin. Cancer Res., June 15, 2009; 15(12): 4220 - 4227.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. Hauschild, S. S. Agarwala, U. Trefzer, D. Hogg, C. Robert, P. Hersey, A. Eggermont, S. Grabbe, R. Gonzalez, J. Gille, et al.
Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma
J. Clin. Oncol., June 10, 2009; 27(17): 2823 - 2830.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Le Tourneau, J. J. Lee, and L. L. Siu
Dose Escalation Methods in Phase I Cancer Clinical Trials
J Natl Cancer Inst, May 20, 2009; 101(10): 708 - 720.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
T. Kurosu, M. Ohki, N. Wu, H. Kagechika, and O. Miura
Sorafenib Induces Apoptosis Specifically in Cells Expressing BCR/ABL by Inhibiting Its Kinase Activity to Activate the Intrinsic Mitochondrial Pathway
Cancer Res., May 1, 2009; 69(9): 3927 - 3936.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Miller, D. J. Murry, K. Owzar, D. R. Hollis, E. B. Kennedy, G. Abou-Alfa, A. Desai, J. Hwang, M. A. Villalona-Calero, E. C. Dees, et al.
Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301
J. Clin. Oncol., April 10, 2009; 27(11): 1800 - 1805.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
N. von Bubnoff, R. A. Engh, E. Aberg, J. Sanger, C. Peschel, and J. Duyster
FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
Cancer Res., April 1, 2009; 69(7): 3032 - 3041.
[Abstract] [Full Text] [PDF]

Home page
 Br. J. Ophthalmol.Home page
J. S Pulido and S. Itty
Systemic antiangiogenic therapy: what goes around...
Br. J. Ophthalmol., April 1, 2009; 93(4): 420 - 421.
[Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
W. W. Ma and A. A. Adjei
Novel Agents on the Horizon for Cancer Therapy
CA Cancer J Clin, March 1, 2009; 59(2): 111 - 137.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. Jilaveanu, C. Zito, S. J. Lee, K. L. Nathanson, R. L. Camp, D. L. Rimm, K. T. Flaherty, and H. M. Kluger
Expression of Sorafenib Targets in Melanoma Patients Treated with Carboplatin, Paclitaxel and Sorafenib
Clin. Cancer Res., February 1, 2009; 15(3): 1076 - 1085.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
R. Houben, H. Voigt, C. Noelke, V. Hofmeister, J. C. Becker, and D. Schrama
MAPK-independent impairment of T-cell responses by the multikinase inhibitor sorafenib
Mol. Cancer Ther., February 1, 2009; 8(2): 433 - 440.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
O. M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner, T. Karrison, E. Manchen, M. Mitchell, M. J. Ratain, and W. M. Stadler
Dynamic Contrast-Enhanced Magnetic Resonance Imaging Pharmacodynamic Biomarker Study of Sorafenib in Metastatic Renal Carcinoma
J. Clin. Oncol., October 1, 2008; 26(28): 4572 - 4578.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
S. M. Wilhelm, L. Adnane, P. Newell, A. Villanueva, J. M. Llovet, and M. Lynch
Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling
Mol. Cancer Ther., October 1, 2008; 7(10): 3129 - 3140.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
T. E. Hutson, R. A. Figlin, J. G. Kuhn, and R. J. Motzer
Targeted Therapies for Metastatic Renal Cell Carcinoma: An Overview of Toxicity and Dosing Strategies
Oncologist, October 1, 2008; 13(10): 1084 - 1096.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. A. Cannistra
Challenges and Pitfalls of Combining Targeted Agents in Phase I Studies
J. Clin. Oncol., August 1, 2008; 26(22): 3665 - 3667.
[Full Text] [PDF]

Home page
 JCOHome page
N. S. Azad, E. M. Posadas, V. E. Kwitkowski, S. M. Steinberg, L. Jain, C. M. Annunziata, L. Minasian, G. Sarosy, H. L. Kotz, A. Premkumar, et al.
Combination Targeted Therapy With Sorafenib and Bevacizumab Results in Enhanced Toxicity and Antitumor Activity
J. Clin. Oncol., August 1, 2008; 26(22): 3709 - 3714.
[Abstract] [Full Text] [PDF]

Home page
 Neuro OncolHome page
C. P. Carden, J. M.G. Larkin, and M. A. Rosenthal
What is the risk of intracranial bleeding during anti-VEGF therapy?
Neuro-oncol, August 1, 2008; 10(4): 624 - 630.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. T. Flaherty, J. Schiller, L. M. Schuchter, G. Liu, D. A. Tuveson, M. Redlinger, C. Lathia, C. Xia, O. Petrenciuc, S. R. Hingorani, et al.
A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel
Clin. Cancer Res., August 1, 2008; 14(15): 4836 - 4842.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
L. Dal Lago, V. D'Hondt, and A. Awada
Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors
Oncologist, August 1, 2008; 13(8): 845 - 858.
[Abstract] [Full Text] [PDF]

Home page
 Therapeutic Advances in GastroenterologyHome page
J. M. Carethers
Review: Systemic treatment of advanced colorectal cancer: Tailoring therapy to the tumor
Therapeutic Advances in Gastroenterology, July 1, 2008; 1(1): 33 - 42.
[Abstract] [PDF]

Home page
 Arch DermatolHome page
J. Autier, B. Escudier, J. Wechsler, A. Spatz, and C. Robert
Prospective Study of the Cutaneous Adverse Effects of Sorafenib, a Novel Multikinase Inhibitor
Arch Dermatol, July 1, 2008; 144(7): 886 - 892.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
M. M. Hipp, N. Hilf, S. Walter, D. Werth, K. M. Brauer, M. P. Radsak, T. Weinschenk, H. Singh-Jasuja, and P. Brossart
Sorafenib, but not sunitinib, affects function of dendritic cells and induction of primary immune responses
Blood, June 15, 2008; 111(12): 5610 - 5620.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
T. Diago, J. S. Pulido, J. R. Molina, L. C. Collet, T. P. Link, and E. H. Ryan Jr
Ranibizumab Combined With Low-Dose Sorafenib for Exudative Age-Related Macular Degeneration
Mayo Clin. Proc., February 1, 2008; 83(2): 231 - 234.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
T. Kuwai, T. Nakamura, S.-J. Kim, T. Sasaki, Y. Kitadai, R. R. Langley, D. Fan, S. R. Hamilton, and I. J. Fidler
Intratumoral Heterogeneity for Expression of Tyrosine Kinase Growth Factor Receptors in Human Colon Cancer Surgical Specimens and Orthotopic Tumors
Am. J. Pathol., February 1, 2008; 172(2): 358 - 366.
[Abstract] [Full Text] [PDF]

Home page
 Am J Health Syst PharmHome page
J. J. Hiles and J. M. Kolesar
Role of sunitinib and sorafenib in the treatment of metastatic renal cell carcinoma
Am. J. Health Syst. Pharm., January 15, 2008; 65(2): 123 - 131.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
W. L. Dahut, C. Scripture, E. Posadas, L. Jain, J. L. Gulley, P. M. Arlen, J. J. Wright, Y. Yu, L. Cao, S. M. Steinberg, et al.
A Phase II Clinical Trial of Sorafenib in Androgen-Independent Prostate Cancer
Clin. Cancer Res., January 1, 2008; 14(1): 209 - 214.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
P. Carpinelli, R. Ceruti, M. L. Giorgini, P. Cappella, L. Gianellini, V. Croci, A. Degrassi, G. Texido, M. Rocchetti, P. Vianello, et al.
PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer
Mol. Cancer Ther., December 1, 2007; 6(12): 3158 - 3168.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B. H. O'Neil and A. P. Venook
Hepatocellular Carcinoma: The Role of the North American GI Steering Committee Hepatobiliary Task Force and the Advent of Effective Drug Therapy
Oncologist, December 1, 2007; 12(12): 1425 - 1432.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Pathol.Home page
L. R Rowe, B. G Bentz, and J. S Bentz
Detection of BRAF V600E activating mutation in papillary thyroid carcinoma using PCR with allele-specific fluorescent probe melting curve analysis
J. Clin. Pathol., November 1, 2007; 60(11): 1211 - 1215.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
H. Akaza, T. Tsukamoto, M. Murai, K. Nakajima, and S. Naito
Phase II Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Sorafenib in Japanese Patients with Advanced Renal Cell Carcinoma
Jpn. J. Clin. Oncol., October 19, 2007; (2007) hym095v1.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
X. W. Meng, S.-H. Lee, H. Dai, D. Loegering, C. Yu, K. Flatten, P. Schneider, N. T. Dai, S. K. Kumar, B. D. Smith, et al.
MCL-1 as a Buffer for Proapoptotic BCL-2 Family Members during TRAIL-induced Apoptosis: A MECHANISTIC BASIS FOR SORAFENIB (BAY 43-9006)-INDUCED TRAIL SENSITIZATION
J. Biol. Chem., October 12, 2007; 282(41): 29831 - 29846.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
R. R. Rosato, J. A. Almenara, S. Coe, and S. Grant
The Multikinase Inhibitor Sorafenib Potentiates TRAIL Lethality in Human Leukemia Cells in Association with Mcl-1 and cFLIPL Down-regulation
Cancer Res., October 1, 2007; 67(19): 9490 - 9500.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. A. Hamstra, A. Rehemtulla, and B. D. Ross
Diffusion Magnetic Resonance Imaging: A Biomarker for Treatment Response in Oncology
J. Clin. Oncol., September 10, 2007; 25(26): 4104 - 4109.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Pharmacol.Home page
M. Rahmani, T. K. Nguyen, P. Dent, and S. Grant
The Multikinase Inhibitor Sorafenib Induces Apoptosis in Highly Imatinib Mesylate-Resistant Bcr/Abl+ Human Leukemia Cells in Association with Signal Transducer and Activator of Transcription 5 Inhibition and Myeloid Cell Leukemia-1 Down-Regulation
Mol. Pharmacol., September 1, 2007; 72(3): 788 - 795.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
I. Duran, S. J. Hotte, H. Hirte, E. X. Chen, M. MacLean, S. Turner, L. Duan, G. R. Pond, C. Lathia, S. Walsh, et al.
Phase I Targeted Combination Trial of Sorafenib and Erlotinib in Patients with Advanced Solid Tumors
Clin. Cancer Res., August 15, 2007; 13(16): 4849 - 4857.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. W. Ryan, B. H. Goldman, P. N. Lara Jr, P. C. Mack, T. M. Beer, C. M. Tangen, D. Lemmon, C.-X. Pan, H. A. Drabkin, and E. D. Crawford
Sorafenib With Interferon Alfa-2b As First-Line Treatment of Advanced Renal Carcinoma: A Phase II Study of the Southwest Oncology Group
J. Clin. Oncol., August 1, 2007; 25(22): 3296 - 3301.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Dasmahapatra, N. Yerram, Y. Dai, P. Dent, and S. Grant
Synergistic Interactions between Vorinostat and Sorafenib in Chronic Myelogenous Leukemia Cells Involve Mcl-1 and p21CIP1 Down-Regulation
Clin. Cancer Res., July 15, 2007; 13(14): 4280 - 4290.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. N. Stein and K. T. Flaherty
CCR Drug Updates: Sorafenib and Sunitinib in Renal Cell Carcinoma
Clin. Cancer Res., July 1, 2007; 13(13): 3765 - 3770.
[Full Text] [PDF]

Home page
 JCOHome page
J. Verweij and M. de Jonge
Multitarget Tyrosine Kinase Inhibition: [And the Winner Is...]
J. Clin. Oncol., June 10, 2007; 25(17): 2340 - 2342.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
T. Guida, S. Anaganti, L. Provitera, R. Gedrich, E. Sullivan, S. M. Wilhelm, M. Santoro, and F. Carlomagno
Sorafenib Inhibits Imatinib-Resistant KIT and Platelet-Derived Growth Factor Receptor {beta} Gatekeeper Mutants
Clin. Cancer Res., June 1, 2007; 13(11): 3363 - 3369.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
A. A. Adjei, J. R. Molina, S. J. Mandrekar, R. Marks, J. R. Reid, G. Croghan, L. J. Hanson, J. R. Jett, C. Xia, C. Lathia, et al.
Phase I Trial of Sorafenib in Combination with Gefitinib in Patients with Refractory or Recurrent Non Small Cell Lung Cancer
Clin. Cancer Res., May 1, 2007; 13(9): 2684 - 2691.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
W. M. Stadler
The randomized discontinuation trial: a phase II design to assess growth-inhibitory agents
Mol. Cancer Ther., April 1, 2007; 6(4): 1180 - 1185.
[Abstract] [Full Text] [PDF]

Home page
 Mayo Clin Proc.Home page
S. Amar, K. J. Wu, and W. W. Tan
Sorafenib-Induced Pancreatitis
Mayo Clin. Proc., April 1, 2007; 82(4): 521 - 521.
[Full Text] [PDF]

Home page
 The OncologistHome page
D. Strumberg, J. W. Clark, A. Awada, M. J. Moore, H. Richly, A. Hendlisz, H. W. Hirte, J. P. Eder, H.-J. Lenz, and B. Schwartz
Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Sorafenib: A Review of Four Phase I Trials in Patients with Advanced Refractory Solid Tumors
Oncologist, April 1, 2007; 12(4): 426 - 437.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. Escudier, N. Lassau, E. Angevin, J. C. Soria, L. Chami, M. Lamuraglia, E. Zafarana, V. Landreau, B. Schwartz, E. Brendel, et al.
Phase I Trial of Sorafenib in Combination with IFN {alpha}-2a in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma or Malignant Melanoma
Clin. Cancer Res., March 15, 2007; 13(6): 1801 - 1809.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
B. I. Rini
Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma: Current Status and Future Directions
Clin. Cancer Res., February 15, 2007; 13(4): 1098 - 1106.
[Abstract] [Full Text] [PDF]

Home page
 Ann. Surg. Oncol.Home page
N. Steeghs, J. W. R. Nortier, and H. Gelderblom
Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
Ann. Surg. Oncol., February 1, 2007; 14(2): 942 - 953.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
C. Gridelli, P. Maione, F. Del Gaizo, G. Colantuoni, C. Guerriero, C. Ferrara, D. Nicolella, D. Comunale, A. De Vita, and A. Rossi
Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer
Oncologist, February 1, 2007; 12(2): 191 - 200.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
K. T. Flaherty
Sorafenib in Renal Cell Carcinoma
Clin. Cancer Res., January 15, 2007; 13(2): 747s - 752s.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
E. Lierman, I. Lahortiga, H. Van Miegroet, N. Mentens, P. Marynen, and J. Cools
The ability of sorafenib to inhibit oncogenic PDGFR{beta} and FLT3 mutants and overcome resistance to other small molecule inhibitors
Haematologica, January 1, 2007; 92(1): 27 - 34.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
R. J. Motzer and R. M. Bukowski
Targeted Therapy for Metastatic Renal Cell Carcinoma
J. Clin. Oncol., December 10, 2006; 24(35): 5601 - 5608.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
E. P. Jane, D. R. Premkumar, and I. F. Pollack
Coadministration of Sorafenib with Rottlerin Potently Inhibits Cell Proliferation and Migration in Human Malignant Glioma Cells
J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1070 - 1080.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. K. Abou-Alfa, L. Schwartz, S. Ricci, D. Amadori, A. Santoro, A. Figer, J. De Greve, J.-Y. Douillard, C. Lathia, B. Schwartz, et al.
Phase II Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma
J. Clin. Oncol., September 10, 2006; 24(26): 4293 - 4300.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
S. Sathornsumetee, A. B. Hjelmeland, S. T. Keir, R. E. McLendon, D. Batt, T. Ramsey, N. Yusuff, B.K. A. Rasheed, M. W. Kieran, A. Laforme, et al.
AAL881, a Novel Small Molecule Inhibitor of RAF and Vascular Endothelial Growth Factor Receptor Activities, Blocks the Growth of Malignant Glioma.
Cancer Res., September 1, 2006; 66(17): 8722 - 8730.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
E. Lierman, C. Folens, E. H. Stover, N. Mentens, H. Van Miegroet, W. Scheers, M. Boogaerts, P. Vandenberghe, P. Marynen, and J. Cools
Sorafenib is a potent inhibitor of FIP1L1-PDGFR{alpha} and the imatinib-resistant FIP1L1-PDGFR{alpha} T674I mutant
Blood, August 15, 2006; 108(4): 1374 - 1376.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. Schoffski, H. Dumez, P. Clement, A. Hoeben, H. Prenen, P. Wolter, S. Joniau, T. Roskams, and H. Van Poppel
Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review
Ann. Onc., August 1, 2006; 17(8): 1185 - 1196.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
A. Morabito, E. De Maio, M. Di Maio, N. Normanno, and F. Perrone
Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
Oncologist, July 1, 2006; 11(7): 753 - 764.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
T. Luft, E. Rodionova, E. Maraskovsky, M. Kirsch, M. Hess, C. Buchholtz, M. Goerner, M. Schnurr, R. Skoda, and A. D. Ho
Adaptive functional differentiation of dendritic cells: integrating the network of extra- and intracellular signals
Blood, June 15, 2006; 107(12): 4763 - 4769.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. J. Ratain, T. Eisen, W. M. Stadler, K. T. Flaherty, S. B. Kaye, G. L. Rosner, M. Gore, A. A. Desai, A. Patnaik, H. Q. Xiong, et al.
Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients With Metastatic Renal Cell Carcinoma
J. Clin. Oncol., June 1, 2006; 24(16): 2505 - 2512.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
H. Richly, B. F. Henning, P. Kupsch, K. Passarge, M. Grubert, R. A. Hilger, O. Christensen, E. Brendel, B. Schwartz, M. Ludwig, et al.
Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors
Ann. Onc., May 1, 2006; 17(5): 866 - 873.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
F. G. Haluska, H. Tsao, H. Wu, F. S. Haluska, A. Lazar, and V. Goel
Genetic alterations in signaling pathways in melanoma.
Clin. Cancer Res., April 1, 2006; 12(7): 2301s - 2307s.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
G. Salvatore, V. De Falco, P. Salerno, T. C. Nappi, S. Pepe, G. Troncone, F. Carlomagno, R. M. Melillo, S. M. Wilhelm, and M. Santoro
BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma
Clin. Cancer Res., March 1, 2006; 12(5): 1623 - 1629.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
D. A. Reardon and P. Y. Wen
Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents.
Oncologist, February 1, 2006; 11(2): 152 - 164.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. P. Hoeflich, D. C. Gray, M. T. Eby, J. Y. Tien, L. Wong, J. Bower, A. Gogineni, J. Zha, M. J. Cole, H. M. Stern, et al.
Oncogenic BRAF Is Required for Tumor Growth and Maintenance in Melanoma Models
Cancer Res., January 15, 2006; 66(2): 999 - 1006.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
W. M. Stadler
New Targets, Therapies, and Toxicities: Lessons to Be Learned
J. Clin. Oncol., January 1, 2006; 24(1): 4 - 5.
[Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
L. L. Siu, A. Awada, C. H. Takimoto, M. Piccart, B. Schwartz, T. Giannaris, C. Lathia, O. Petrenciuc, and M. J. Moore
Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer
Clin. Cancer Res., January 1, 2006; 12(1): 144 - 151.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. Arora and E. M. Scholar
Role of Tyrosine Kinase Inhibitors in Cancer Therapy
J. Pharmacol. Exp. Ther., December 1, 2005; 315(3): 971 - 979.
[Abstract] [Full Text] [PDF]

Home page
 ASH ANNUAL MEETING ABSTRACTSHome page
J. W. Smith, H. Powell, A. Tefferi, S. H. Kaufmann, T. Lasho, D. Loegerling, M. Galvez, and R. Mesa
Evaluation of the In Vitro Activity of the Multikinase Inhibitor BAY 43-9006 (Sorafenib) in Primary Cells from Patients with Myelofibrosis with Myeloid Metaplasia (MMM).
Blood (ASH Annual Meeting Abstracts), November 16, 2005; 106(11): 4943 - 4943.
[Abstract]

Home page
 JCOHome page
R. D. Loberg, C. J. Logothetis, E. T. Keller, and K. J. Pienta
Pathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
J. Clin. Oncol., November 10, 2005; 23(32): 8232 - 8241.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. Moore, H. W. Hirte, L. Siu, A. Oza, S. J. Hotte, O. Petrenciuc, F. Cihon, C. Lathia, and B. Schwartz
Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors
Ann. Onc., October 1, 2005; 16(10): 1688 - 1694.
[Abstract] [Full Text] [PDF]

Home page
 CA Cancer J ClinHome page
K. J. Pienta and D. C. Smith
Advances in Prostate Cancer Chemotherapy: A New Era Begins
CA Cancer J Clin, September 1, 2005; 55(5): 300 - 318.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
A. A. Adjei and M. Hidalgo
Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy
J. Clin. Oncol., August 10, 2005; 23(23): 5386 - 5403.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. J. Cohen, R. B. Cohen, and N. J. Meropol
Targeting Signal Transduction Pathways in Colorectal Cancer--More Than Skin Deep
J. Clin. Oncol., August 10, 2005; 23(23): 5374 - 5385.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J.-C. Barbare, O. Bouche, F. Bonnetain, J.-L. Raoul, P. Rougier, A. Abergel, V. Boige, B. Denis, A. Blanchi, A. Pariente, et al.
Randomized Controlled Trial of Tamoxifen in Advanced Hepatocellular Carcinoma
J. Clin. Oncol., July 1, 2005; 23(19): 4338 - 4346.
[Abstract] [Full Text] [PDF]


About
JCO		 Editorial
Roster		 Advertising
Information		 Librarians &
Institutions		 Rights &
Permissions		 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online